Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication
AntengeneHKG: 6996

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch
CVDEverest Medicines

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic
GlaxoSmithKlineGSK

GSK’s Exdensur Wins FDA Approval as First Twice‑Yearly Asthma Biologic

Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo
AdageneNASDAQ: ADAG

Adagene’s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo

Show More